# Sendai Kousei Hospital

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/sendai-kousei-hospital/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 50 |
| Citations | 73,089 |
| City | Sendai |
| Country | JP |
| Description | Sendai Kousei Hospital is a research organisation in Sendai, JP. OpenAlex records 2,301 works and 73,089 citations for it. 595 researchers list it as their most recent affiliation. |
| Homepage | http://www.sendai-kousei-hospital.jp/ |
| OpenAlex ID | https://openalex.org/I4210166385 |
| Researchers | 595 |
| ROR ID | https://ror.org/05yevkn97 |
| Type | healthcare |
| Works | 2,301 |

## University papers

- [Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-for-squamous-non-small-cell-lung-cancer/)
- [Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial](https://scholariq.org/papers/adjuvant-atezolizumab-after-adjuvant-chemotherapy-in-resected-stage-ib-iiia-non/)
- [Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC](https://scholariq.org/papers/osimertinib-with-or-without-chemotherapy-in-i-egfr-i-mutated-advanced-nsclc/)
- [Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-in-squamous-non-small-cell-lung-cancer-5-year/)
- [Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer](https://scholariq.org/papers/multisystem-immune-related-adverse-events-associated-with-immune-checkpoint/)
- [Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer](https://scholariq.org/papers/nivolumab-with-carboplatin-paclitaxel-and-bevacizumab-for-first-line-treatment/)
- [Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L](https://scholariq.org/papers/randomized-phase-iii-study-comparing-gefitinib-with-erlotinib-in-patients-with/)

## University top topics

Showing 8 of 25.

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Peripheral Artery Disease Management](https://scholariq.org/topics/peripheral-artery-disease-management/)
- [Cardiac Valve Diseases and Treatments](https://scholariq.org/topics/cardiac-valve-diseases-and-treatments/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Coronary Interventions and Diagnostics](https://scholariq.org/topics/coronary-interventions-and-diagnostics/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.